COR
Coresite Realty CorporationCOR
COR
Delisted
COR was delisted on the 27th of December, 2021.
Financial journalist opinion
Positive
Zacks Investment Research
3 days ago
Is Cencora, Inc. (COR) Stock Outpacing Its Medical Peers This Year?
Here is how Cencora (COR) and Catalyst Pharmaceutical (CPRX) have performed compared to their sector so far this year.
Positive
Zacks Investment Research
6 days ago
Here's Why You Should Add Cencora Stock to Your Portfolio Now
COR continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
Neutral
Business Wire
1 week ago
Cencora Elects Lori J. Ryerkerk to Its Board of Directors
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that its Board of Directors has elected Lori J. Ryerkerk as a new independent director, effective June 1, 2025. “Ms. Ryerkerk's experience in complex, global supply chains will further strengthen the Board's expertise as we continue supporting the company's long-term growth. Her appointment reflects the Cencora Board's ongoing commitment to leaders who can help us contribute to driving stakeholder value,” said Mark Du.
Positive
Seeking Alpha
2 weeks ago
Cencora Continues To Deliver As A Healthcare Distributor With Further Growth Signs
Cencora gets a buy rating, agreeing with today's consensus from Wall St. The sector and macro environment points to continued demand for the healthcare supplies and niche specialty drugs Cencora can distribute. Future share price targets point to significant potential upside over 3 years, justifying a buy despite the stock trading above average now.
Positive
Zacks Investment Research
3 weeks ago
Here's Why Cencora (COR) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Positive
Zacks Investment Research
4 weeks ago
Cencora, Inc. (COR) Hits Fresh High: Is There Still Room to Run?
Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Positive
Zacks Investment Research
4 weeks ago
Cencora (COR) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Cencora (COR) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Positive
Zacks Investment Research
4 weeks ago
COR Q2 Earnings & Revenues Beat Estimates, '25 EPS Guidance Raised
COR's second-quarter fiscal 2025 results showcase a strong segmental performance. The company's earnings guidance for fiscal 2025 looks encouraging.
Positive
Benzinga
4 weeks ago
Cencora's Boosts Annual Forecast On Strong Demand For Weight Loss Drugs, Specialty Products Despite Mixed Q2 Earnings
Cencora, Inc COR on Wednesday reported second-quarter 2025 sales increased 10.3% to $75.5 billion, missing the consensus of $75.68 billion, primarily due to an 11.4% increase in revenue within the U.S. Healthcare Solutions segment.
Neutral
Seeking Alpha
4 weeks ago
Cencora, Inc. (COR) Q2 2025 Earnings Call Transcript
Cencora, Inc. (NYSE:COR ) Q2 2025 Earnings Conference Call May 7, 2025 8:30 AM ET Company Participants Bennett Murphy - Senior Vice President, Head of Investor Relations & Treasury Bob Mauch - President & Chief Executive Officer Jim Cleary - Executive Vice President & Chief Financial Officer Conference Call Participants Elizabeth Anderson - Evercore ISI Michael Cherny - Leerink Capital Lisa Gill - JPMorgan George Hill - Deutsche Bank Charles Rhyee - TD Cowen Eric Percher - Nephron Research Steven Valiquette - Mizuho Securities Allen Lutz - Bank of America Daniel Grosslight - Citi Kevin Caliendo - UBS Erin Wright - Morgan Stanley Operator Hello, everyone, and thank you for joining the Cencora Fiscal 2025 Second Quarter Results Conference Call. My name is Lucy, and I will be coordinating your call today.
Charts implemented using Lightweight Charts™